as 05-20-2024 9:33am EST
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
Founded: | 2013 | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 886.5M | IPO Year: | N/A |
Target Price: | $32.00 | AVG Volume (30 days): | 68.0K |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.73 | EPS Growth: | N/A |
52 Week Low/High: | $8.00 - $17.02 | Next Earning Date: | 04-02-2024 |
Revenue: | $5,134,444 | Revenue Growth: | N/A |
Revenue Growth (this year): | -79.39% | Revenue Growth (next year): | 6427.41% |
ABVX Breaking Stock News: Dive into ABVX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 months ago
CNW Group
4 months ago
PR Newswire
4 months ago
Business Wire
4 months ago
Zacks
4 months ago
GlobeNewswire
4 months ago
Zacks
4 months ago
Zacks
4 months ago